# US 2006/0068370 A1 · Liver specific chimeric regulatory sequence and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0068370 A1
- Document ID: US20060068370A1
- Status: Published application
- Kind: A1
- Application number: 11/030,110
- Filed: 2005-01-07
- Published: 2006-03-30
- Earliest claimed: 2004-09-30
- Assignees: Industrial Technology Research Institute
- Inventors: Mei-Chih Wang; Chin-Yu Lin; Hui-Ti Lin; Mei-Hwei Fan-Chiang
- Web page: https://patentgrep.com/patent/US20060068370A1

## CPC

- G01N 33/5067: {Liver cells}
- C12N 15/85: for animal cells
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/85: mammalian
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a chimeric regulatory sequence with liver cell specificity. The chimeric regulatory sequence includes a proximal regulatory sequence and a distal enhancer of 5′ flanking region of human α-fetoprotein (AFP) gene. The chimeric regulatory sequence is useful in purified specific cell lineages, such as liver cells, from other cell lineages.

## Claims

### Claim 1

A chimeric regulatory sequence with liver cell specificity, wherein the nucleotide sequence is SEQ ID NO. 1.

### Claim 2 (depends on 1)

The regulatory sequence as claimed in claim 1, wherein said sequence comprises a proximal regulatory sequence and a distal enhancer of the 5′ flanking region of human α-fetoprotein (AFP) gene.

### Claim 3 (depends on 1)

The regulatory sequence as claimed in claim 1, wherein a target gene operably linked to said regulatory sequence is activated in liver cells.

### Claim 4

A method for purifying liver cells from a heterogeneous population of cells, comprising the steps:
(a) transfecting the cells with a DNA fragment encoding a selectable marker under a regulatory sequence that is specifically activating in liver cells;
(b) separating those cells expressing the selectable marker from the population of cells; and
(c) obtaining purified liver cells.

### Claim 5 (depends on 4)

The method as claimed in claim 4, wherein the nucleotide sequence of said regulatory sequence is SEQ ID NO. 1.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the selectable marker is a fluorescent marker.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the fluorescent marker is selected from green fluorescent protein, lacZ, firefly Rennila protein, luciferase, red cyan protein and yellow cyan protein.

### Claim 8 (depends on 6)

The method as claimed in claim 6, wherein the fluorescent marker is enhanced green fluorescent protein.

### Claim 9 (depends on 4)

The method as claimed in claim 4, wherein (b) further comprises separating the cells containing the marker from the population of cells using a fluorescent activated cell sorter or a laser scanning cytometer.

### Claim 10 (depends on 4)

The method as claimed in claim 4, wherein the selectable marker is an antibiotic resistance marker.

### Claim 11 (depends on 4)

The method as claimed in claim 4, wherein step (b) further comprises separating cells by culturing the cells in a selective medium containing antibiotics.

### Claim 12 (depends on 4)

The method as claimed in claim 4, wherein the cells are transfected by lipofection.

### Claim 13 (depends on 4)

The method as claimed in claim 4, wherein further comprises a step (d) after step (c), identifying said purified cells with immunostaining method.

### Claim 14 (depends on 13)

The method as claimed in claim 13, wherein said immunostaining method in step (d) is used to examine the α-fetoprotein expression in the purified cells.
